Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102497 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL103308 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL201001 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL199750 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL102914 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL101878 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL7888892 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL7939027 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL101629 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR | |
| SCHEMBL103793 | 1.00 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024147345-A1 | COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, LITHIUM ION BATTERY, AND METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES | ＡＰＢ株式会社 | 2024-07-11 | — | — | WO | disclosed |
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-20240182746-A1 | POLYMER COMPOSITION COMPRISING POLYACRYLIC BLOCK COPOLYMER AND AROMATIC BASED POLYALKYLENEOXIDE AS DISPERSANT | BASF SE (DE) | 2024-06-06 | — | — | US | disclosed |
| WO-2024042211-A1 | A POLYETHER-BASED DISPERSANT WITH A LIGHT STABILIZING EFFECT | BASF SE (DE) | 2024-02-29 | — | — | WO | disclosed |
| US-20240024252-A1 | LIPID NANOPARTICLE | NITTO DENKO CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| WO-2024018762-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| WO-2024018761-A1 | NEUTRAL LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| CN-117062872-A | Polymer composition comprising a polyacrylic block copolymer and an aromatic polyoxyalkylene as dispersant | 巴斯夫欧洲公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023204215-A1 | ELECTRODE COMPOSITION FOR LITHIUM ION BATTERIES, COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, AND LITHIUM ION BATTERY | ＡＰＢ株式会社 | 2023-10-26 | — | — | WO | disclosed |
| WO-2023188830-A1 | LIPID NANOPARTICLES | 国立大学法人北海道大学 | 2023-10-05 | — | — | WO | disclosed |
| CN-1208035-A | Dithiolan derivatives, their preparation and their therapeutic effect | SANKYO CO (JP) | 1999-02-17 | — | — | CN | disclosed |
| EP-0869126-A1 | Dithiolan derivatives, their preparation and their therapeutic effect | Sankyo Company Limited (JP) | 1998-10-07 | — | — | EP | disclosed |
| US-4569940-A | Certain 5-N-mono- or disubstituted sulfamoyl benzamides having use in treatment of emesis, impaired gastro-intestinal motility disorders and central nervous system disorders | BEECHAM GROUP P.L.C. (GB) | 1986-02-11 | — | — | US | disclosed |
| EP-0096524-A2 | Bicyclic benzamides or anilides, process for their preparation, and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-12-21 | — | — | EP | disclosed |
| US-4251469-A | ADDITIVES FOR EXTREME PRESSURE LUBRICANTS | CIBA-GEIGY CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| US-4246127-A | POLYOXYALKYLENE-MERCAPTANS USEFUL IN EXTREME PRESSURE APPLICATIONS | CIBA-GEIGY CORPORATION (US) | 1981-01-20 | — | — | US | disclosed |
| US-4197209-A | Lubricant compositions containing sulfur-containing esters of phosphoric acid | CIBA-GEIGY CORPORATION (US) | 1980-04-08 | — | — | US | disclosed |
| US-4189453-A | FROM MERCAPTANS AND PHOSPHORUS TRIHALIDE, CATALYTIC | CIBA-GEIGY CORPORATION (US) | 1980-02-19 | — | — | US | disclosed |
| US-4147666-A | MERCAPTANS, THIOETHERS, DISULFIDES AND POLYSULFIDES | CIBA-GEIGY AG (CH) | 1979-04-03 | — | — | US | disclosed |
| US-4001314-A | PROSTAGLANDINS, BRONCHODILATORS, ANTISECRETORY AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024252-A1 | LIPID NANOPARTICLE | LIPC, ACOX1, ABCB4 | ACE2 2922/4885OPRM1 1547/4885SPHK1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.